JLE

Epileptic Disorders

MENU

Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy Volume 21, issue 6, December 2019

  • [Abe et al., 2014] Abe K., Hamada H., Yamada T., Obata-Yasuoka M., Minakami H., Yoshikawa H. Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. Seizure. 2014;23:112-116. 2
  • [Adab et al., 2001] Adab N., Jacoby A., Smith D., Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001;70:15-21. 1
  • [Adab et al., 2004] Adab N., Kini U., Vinten J. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75:1575-1583. 11
  • [Almgren et al., 2009] Almgren M., Kallen B., Lavebratt C. Population-based study of antiepileptic drug exposure in utero-influence on head circumference in newborns. Seizure. 2009;18:672-675. 10
  • [Baker et al., 2015] Baker G.A., Bromley R.L., Briggs M. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84:382-390. 4
  • [Battino et al., 1999] Battino D., Kaneko S., Andermann E. Intrauterine growth in the offspring of epileptic women: a prospective multicenter study. Epilepsy Res. 1999;36:53-60. 1
  • [Battino et al., 2013] Battino D., Tomson T., Bonizzoni E. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry. Epilepsia. 2013;54:1621-1627. 9
  • [Bech et al., 2018] Bech L.F., Polcwiartek C., Kragholm K. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry. 2018;89:1324-1331. 12
  • [Betts and Fox, 1999] Betts T., Fox C. Proactive pre-conception counselling for women with epilepsy-is it effective? Seizure. 1999;8:322-327. 6
  • [Bjork et al., 2018] Bjork M., Riedel B., Spigset O. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs in utero. JAMA Neurol. 2018;75:160-168. 2
  • [Blotière et al., 2019] Blotière P.O., Raguideau F., Weill A. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019;93:e167-e180. 2
  • [Blümcke et al., 2019] Blümcke I., Arzimanoglou A., Beniczky S., Wiebe S. Roadmap for a competency-based educational curriculum in epileptology: report of the Epilepsy Education Task Force of the International League Against Epilepsy. Epileptic Disord. 2019;21:129-140. 2
  • [Borthen et al., 2011] Borthen I., Eide M.G., Daltveit A.K., Gilhus N.E. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. BJOG. 2011;118:956-965. 8
  • [Bromley et al., 2010] Bromley R.L., Mawer G., Love J. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51:2058-2065. 10
  • [Bromley et al., 2013] Bromley R.L., Mawer G.E., Briggs M. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84:637-643. 6
  • [Bromley et al., 2014] Bromley R.L., Weston J., Adab N. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10:CD010236.
  • [Bromley et al., 2016] Bromley R.L., Calderbank R., Cheyne C.P. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;87:1943-1953. 18
  • [Bromley et al., 2019] Bromley R.L., Baker G.A., Clayton-Smith J., Wood A.G. Intellectual functioning in clinically confirmed fetal valproate syndrome. Neurotoxicol Teratol. 2019;71:16-21.
  • [Cagnetti et al., 2014] Cagnetti C., Lattanzi S., Foschi N., Provinciali L., Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;83:339-344. 4
  • [Campbell et al., 2013] Campbell E., Devenney E., Morrow J. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia. 2013;54:165-171. 1
  • [Campbell et al., 2014] Campbell E., Kennedy F., Russell A. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85:1029-1034. 9
  • [Centers for Disease Control, 1992] Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992; 41(RR-14): 1-7.
  • [Chatzi et al., 2012] Chatzi L., Papadopoulou E., Koutra K. Effect of high doses of folic acid supplementation in early pregnancy on child neurodevelopment at 18 months of age: the mother-child cohort ’Rhea’ study in Crete, Greece. Public Health Nutr. 2012;15:1728-1736. 9
  • [Chen et al., 2009] Chen Y.H., Chiou H.Y., Lin H.C., Lin H.L. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol. 2009;66:979-984. 8
  • [Christensen et al., 2013] Christensen J., Gronborg T.K., Sorensen M.J. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696-1703. 16
  • [Christensen et al., 2019] Christensen J., Pedersen L.H., Sun Y., Dreier J.W., Brikell I., Dalsgaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Netw Open. 2019;2:e186606. 1
  • [Cohen et al., 2011] Cohen M.J., Meador K.J., Browning N. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy Behav. 2011;22:240-246. 2
  • [Cohen et al., 2019] Cohen M.J., Meador K.J., May R. Fetal antiepileptic drug exposure and learning and memory functioning at 6years of age: the NEAD prospective observational study. Epilepsy Behav. 2019;92:154-164.
  • [Crawford and Hudson, 2003] Crawford P., Hudson S. Understanding the information needs of women with epilepsy at different lifestages: results of the ‘Ideal World’ survey. Seizure. 2003;12:502-507. 7
  • [Cummings et al., 2011] Cummings C., Stewart M., Stevenson M., Morrow J., Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011;96:643-647. 7
  • [Czeizel et al., 2013] Czeizel A.E., Dudas I., Vereczkey A., Banhidy F. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients. 2013;5:4760-4775. 11
  • [De Jong et al., 2016] De Jong J., Garne E., De Jong-Van Den Berg L.T., Wang H. The risk of specific congenital anomalies in relation to newer antiepileptic drugs: a literature review. Drugs Real World Outcomes. 2016;3:131-143. 2
  • [Donaldson, 2002] Donaldson, Donaldson JO. Neurological disorders. In: Swiet MD. Medical disorders in obstetric practice.4th Ed. London: Blackwell Science Ltd., 2002: 486-9.
  • [Edey et al., 2014] Edey S., Moran N., Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia. 2014;55:e72-e74. 7
  • [Elkjaer et al., 2018] Elkjaer L.S., Bech B.H., Sun Y., Laursen T.M., Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurol. 2018;75:663-671. 6
  • [European Medicines and Agency, 2018] European Medicines Agency. Assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500177352.pdf. Accessed April 10, 2018.
  • [FDA, 2017] FDA. Drug Safety Communication: Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. (Issued June 5, 2013). Available at: https://www.fda.gov/Drugs/DrugSafety/ucm350684.htm. Accessed September 12, 2017.
  • [Fisher et al., 2017] Fisher R.S., Cross J.H., French J.A. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522-530. 4
  • [Forsberg et al., 2011] Forsberg L., Wide K., Kallen B. School performance at age 16 in children exposed to antiepileptic drugs in utero-a population-based study. Epilepsia. 2011;52:364-369. 2
  • [Frankenburg, 2009] Frankenburg F.R. Folate supplementation: is it safe and effective? J Clin Psychiatry. 2009;70:767. 5
  • [Gaily et al., 1988] Gaily E., Kantola-Sorsa E., Granström M.L. Intelligence of children of epileptic mothers. J Pediatr. 1988;113:677-684. 4
  • [Gaily et al., 1990] Gaily E.K., Granström M.L., Hiilesmaa V.K., Bardy A.H. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res. 1990;5:217-222. 3
  • [Gaily et al., 2004] Gaily E., Kantola-Sorsa E., Hiilesmaa V. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004;62:28-32. 1
  • [Galanti et al., 2009] Galanti M., Newport D.J., Pennell P.B. Postpartum depression in women with epilepsy: influence of antiepileptic drugs in a prospective study. Epilepsy Behav. 2009;16:426-430. 3
  • [Harden et al., 2009a] Harden C.L., Pennell P.B., Koppel B.S. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin k, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:142-149. 2
  • [Harden et al., 2009b] Harden C.L., Meador K.J., Pennell P.B. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50:1237-1246. 5
  • [Hernandez-Diaz et al., 2012] Hernandez-Diaz S., Smith C.R., Shen A. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692-1699. 21
  • [Hernandez-Diaz et al., 2017] Hernandez-Diaz S., Mcelrath T.F., Pennell P.B., Hauser W.A., Yerby M., Holmes L.B. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol. 2017;82:457-465. 3
  • [Hernandez-Diaz et al., 2018] Hernandez-Diaz S., Huybrechts K.F., Desai R.J. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology. 2018;90:e342-e351. 4
  • [Herzog et al., 2017] Herzog A.G., Mandle H.B., Cahill K.E., Fowler K.M., Hauser W.A. Predictors of unintended pregnancy in women with epilepsy. Neurology. 2017;88:728-733. 8
  • [Hiilesmaa and Teramo, 2013] Hiilesmaa V, Teramo K. Fetal and maternal risks with seizures. In: Harden C, Thomas SV, Tomson T, Hoboken NJ. Epilepsy in women. Wiley-Blackwell, 2013: 115-27.
  • [Hiilesmaa et al., 1981] Hiilesmaa V.K., Teramo K., Granström M.L., Bardy A.H. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet. 1981;2:165-167. 8239
  • [Holmes et al., 2011] Holmes L.B., Mittendorf R., Shen A., Smith C.R., Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68:1275-1281. 10
  • [Huber-Mollema et al., 2019] Huber-Mollema Y., Oort F.J., Lindhout D., Rodenburg R. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia. 2019;60:1069-1082. 6
  • [Hunt et al., 2008] Hunt S., Russell A., Smithson W.H. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71:272-276. 4
  • [Husebye et al., 2018] Husebye E.S.N., Gilhus N.E., Riedel B., Spigset O., Daltveit A.K., Bjork M.H. Verbal abilities in children of mothers with epilepsy: association to maternal folate status. Neurology. 2018;91:e811-e821. 9
  • [Hvas et al., 2000] Hvas C.L., Henriksen T.B., Ostergaard J.R., Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. BJOG. 2000;107:896-902. 7
  • [Ip et al., 2009] Ip S., Chung M., Raman G., Trikalinos T.A., Lau J. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med. 2009;4:S17-30. 1
  • [Johannessen Landmark et al., 2017] Johannessen Landmark C., Burns M.L., Baftiu A. Pharmacokinetic variability of valproate in women of childbearing age. Epilepsia. 2017;58:e142-e146. 10
  • [Johnson et al., 2014] Johnson E.L., Stowe Z.N., Ritchie J.C. Carbamazepine clearance and seizure stability during pregnancy. Epilepsy Behav. 2014;33:49-53.
  • [Julvez et al., 2009] Julvez J., Fortuny J., Mendez M., Torrent M., Ribas-Fito N., Sunyer J. Maternal use of folic acid supplements during pregnancy and four-year-old neurodevelopment in a population-based birth cohort. Paediatr Perinat Epidemiol. 2009;23:199-206. 3
  • [Karanam et al., 2018] Karanam A., Pennell P.B., French J.A. Lamotrigine clearance increases by 5 weeks gestational age: relationship to estradiol concentrations and gestational age. Ann Neurol. 2018;84:556-563. 4
  • [Keni et al., 2018] Keni R.R., Jose M., Sarma P.S., Thomas S.V. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both? Neurology. 2018;90:e790-e796. Kerala Registry of Epilepsy, Pregnancy Study Group9
  • [Kilic et al., 2014] Kilic D., Pedersen H., Kjaersgaard M.I. Birth outcomes after prenatal exposure to antiepileptic drugs-a population-based study. Epilepsia. 2014;55:1714-1721. 11
  • [Kinney and Morrow, 2016] Kinney M.O., Morrow J. Epilepsy in pregnancy. BMJ. 2016;353:i2880.
  • [Kinney et al., 2018] Kinney M.O., Morrow J., Patterson C.C. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. J Neurol Neurosurg Psychiatry. 2018;89:1320-1323. 12
  • [Lopez-Fraile et al., 2009] Lopez-Fraile I.P., Cid A.O., Juste A.O., Modrego P.J. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav. 2009;15:372-375. 3
  • [Macdonald et al., 2015] Macdonald S.C., Bateman B.T., Mcelrath T.F., Hernandez-Diaz S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA Neurol. 2015;72:981-988. 9
  • [Margulis et al., 2019] Margulis A.V., Hernandez-Diaz S., McElrath T. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One. 2019;14:e0214180. 8
  • [Mawhinney et al., 2012] Mawhinney E., Campbell J., Craig J. Valproate and the risk for congenital malformations: is formulation and dosage regime important? Seizure. 2012;21:215-218. 3
  • [Mawhinney et al., 2013] Mawhinney E., Craig J., Morrow J. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80:400-405. 4
  • [Mcgrath et al., 2014] Mcgrath A., Sharpe L., Lah S., Parratt K. Pregnancy-related knowledge and information needs of women with epilepsy: a systematic review. Epilepsy Behav. 2014;31:246-255.
  • [Meadow, 1968] Meadow S.R. Anticonvulsant drugs and congenital abnormalities. Lancet. 1968;2:1296. 7581
  • [Meador et al., 2009] Meador K.J., Baker G.A., Browning N. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360:1597-1605. 16
  • [Meador et al., 2010] Meador K.J., Baker G.A., Browning N. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology. 2010;75:1954-1960. 22
  • [Meador et al., 2011] Meador K.J., Baker G.A., Browning N. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011;134:396-404. 2
  • [Meador et al., 2013] Meador K.J., Baker G.A., Browning N. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12:244-252. 3
  • [Meador et al., 2014] Meador K.J., Baker G.A., Browning N. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168:729-736. 8
  • [Meador et al., 2018] Meador K.J., Pennell P.B., May R.C. Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy. Epilepsy Behav. 2018;84:10-14.
  • [Moore et al., 2000] Moore S.J., Turnpenny P., Quinn A. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet. 2000;37:489-497. 7
  • [Morris et al., 2010] Morris M.S., Jacques P.F., Rosenberg I.H., Selhub J. Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. Am J Clin Nutr. 2010;91:1733-1744. 6
  • [Morrow et al., 2006] Morrow J., Russell A., Guthrie E. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193-198. 2
  • [Morrow et al., 2009] Morrow J.I., Hunt S.J., Russell A.J. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2009;80:506-511. 5
  • [Vitamin Study Research Group, 1991] MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137. 8760
  • [Murray et al., 2018] Murray L.K., Smith M.J., Jadavji N.M. Maternal oversupplementation with folic acid and its impact on neurodevelopment of offspring. Nutr Rev. 2018;76:708-721. 9
  • [Nadebaum et al., 2011] Nadebaum C., Anderson V., Vajda F., Reutens D., Barton S., Wood A. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011;17:133-142. 1
  • [Nei et al., 1998] Nei M., Daly S., Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology. 1998;51:904-906. 3
  • [NICE, 2012] NICE. Epilepsies: Diagnosis And Management. 2012.
  • [Pennell, 2013] Pennell PB. Pregnancy, epilepsy, and women's issues. Continuum (Minneap Minn) 2013; 19(3 Epilepsy): 697-714.
  • [Pennell and McElrath, 2019] Pennell and McElrath, Pennell PB, McElrath T. Risks associated with epilepsy during pregnancy and postpartum period. In: Dashe JF. UpToDate. UpToDate Inc: Waltham, MA. (Accessed on March 13, 2019).
  • [Pennell et al., 2008] Pennell P.B., Peng L., Newport D.J. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70:2130-2136. 22
  • [Pennell et al., 2012] Pennell P.B., Klein A.M., Browning N. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012;24:449-456. 4
  • [Polepally et al., 2014] Polepally A.R., Pennell P.B., Brundage R.C. Model-based lamotrigine clearance changes during pregnancy: clinical implication. Ann Clin Transl Neurol. 2014;1:99-106. 2
  • [Rasalam et al., 2005] Rasalam A.D., Hailey H., Williams J.H. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol. 2005;47:551-555. 8
  • [Reisinger et al., 2013] Reisinger T.L., Newman M., Loring D.W., Pennell P.B., Meador K.J. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013;29:13-18. 1
  • [Rihtman et al., 2012] Rihtman T., Parush S., Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol. 2012;34:308-311. 3
  • [Rihtman et al., 2013] Rihtman T., Parush S., Ornoy A. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. Reprod Toxicol. 2013;41:115-125.
  • [Roth et al., 2011] Roth C., Magnus P., Schjolberg S. Folic acid supplements in pregnancy and severe language delay in children. JAMA. 2011;306:1566-1573. 14
  • [Rovet et al., 1995] Rovet J., Cole S., Nulman I., Scolnik D., Altmann D., Koren G. Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology. 1995;1:150-157. 2
  • [Roza et al., 2010] Roza S.J., Van Batenburg-Eddes T., Steegers E.A. Maternal folic acid supplement use in early pregnancy and child behavioural problems: The Generation R Study. Br J Nutr. 2010;103:445-452. 3
  • [Rozendaal et al., 2013] Rozendaal A.M., van Essen A.J., te Meerman G.J. Periconceptional folic acid associated with an increased risk of oral clefts relative to non-folate related malformations in the Northern Netherlands: a population based case-control study. Eur J Epidemiol. 2013;28:875-887. 11
  • [Sahoo and Klein, 2005] Sahoo S., Klein P. Maternal complex partial seizure associated with fetal distress. Arch Neurol. 2005;62:1304-1305. 8
  • [Schlotz et al., 2010] Schlotz W., Jones A., Phillips D.I., Gale C.R., Robinson S.M., Godfrey K.M. Lower maternal folate status in early pregnancy is associated with childhood hyperactivity and peer problems in offspring. J Child Psychol Psychiatry. 2010;51:594-602. 5
  • [Scolnik et al., 1994] Scolnik D., Nulman I., Rovet J. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA. 1994;271:767-770. 10
  • [Shallcross et al., 2011] Shallcross R., Bromley R.L., Irwin B., Bonnett L.J., Morrow J., Baker G.A. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011;76:383-389. 4
  • [Shallcross et al., 2014] Shallcross R., Bromley R.L., Cheyne C.P. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology. 2014;82:213-221. 3
  • [Skorka et al., 2012] Skorka A., Gieruszczak-Bialek D., Piescik M., Szajewska H. Effects of prenatal and/or postnatal (maternal and/or child) folic acid supplementation on the mental performance of children. Crit Rev Food Sci Nutr. 2012;52:959-964. 11
  • [Sveberg et al., 2015] Sveberg L., Svalheim S., Tauboll E. The impact of seizures on pregnancy and delivery. Seizure. 2015;28:35-38.
  • [Thomas et al., 2008] Thomas S.V., Ajaykumar B., Sindhu K., Nair M.K., George B., Sarma P.S. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008;13:229-236. 1
  • [Thomas et al., 2012] Thomas S.V., Syam U., Devi J.S. Predictors of seizures during pregnancy in women with epilepsy. Epilepsia. 2012;53:e85-e88. 5
  • [Tomson et al., 2007] Tomson T., Palm R., Kallen K. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48:1111-1116. 6
  • [Tomson et al., 2010] Tomson T., Battino D., Craig J. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia. 2010;51:909-915. 5
  • [Tomson et al., 2013] Tomson T., Johannessen Landmark C., Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-414. 3
  • [Tomson et al., 2015] Tomson T., Battino D., Bonizzoni E. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology. 2015;85:866-872. 10
  • [Tomson et al., 2016] Tomson T., Battino D., Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15:210-218. 2
  • [Tomson et al., 2018] Tomson T., Battino D., Bonizzoni E. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530-538. 6
  • [Tomson et al., 2019] Tomson T., Battino D., Bonizzoni E. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology. 2019;93:e831-e840. 9
  • [Turner et al., 2006] Turner K., Piazzini A., Franza A. Postpartum depression in women with epilepsy versus women without epilepsy. Epilepsy Behav. 2006;9:293-297. 2
  • [Vajda et al., 2008] Vajda F.J., Hitchcock A., Graham J., O’brien T., Lander C., Eadie M. Seizure control in antiepileptic drug-treated pregnancy. Epilepsia. 2008;49:172-176. 1
  • [Vajda et al., 2013] Vajda F.J., O’brien T.J., Lander C.M., Graham J., Roten A., Eadie M.J. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia. 2013;54:181-186. 1
  • [Veiby et al., 2009] Veiby G., Daltveit A.K., Engelsen B.A., Gilhus N.E. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia. 2009;50:2130-2139. 9
  • [Veiby et al., 2013a] Veiby G., Daltveit A.K., Schjolberg S. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013;54:1462-1472. 8
  • [Veiby et al., 2013b] Veiby G., Engelsen B.A., Gilhus N.E. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013;70:1367-1374. 11
  • [Veiby et al., 2014] Veiby G., Daltveit A.K., Engelsen B.A., Gilhus N.E. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579-588. 3
  • [Veroniki et al., 2017] Veroniki A.A., Cogo E., Rios P. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15:95. 1
  • [Villamor et al., 2012] Villamor E., Rifas-Shiman S.L., Gillman M.W., Oken E. Maternal intake of methyl-donor nutrients and child cognition at 3 years of age. Paediatr Perinat Epidemiol. 2012;26:328-335. 4
  • [Voinescu and Pennell, 2017] Voinescu P.E., Pennell P.B. Delivery of a personalized treatment approach to women with epilepsy. Semin Neurol. 2017;37:611-623. 6
  • [Voinescu et al., 2018] Voinescu P.E., Park S., Chen L.Q. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018;91:e1228-e1236. 13
  • [Wehby and Murray, 2008] Wehby G.L., Murray J.C. The effects of prenatal use of folic acid and other dietary supplements on early child development. Matern Child Health J. 2008;12:180-187. 2
  • [Westin et al., 2008] Westin A.A., Reimers A., Helde G., Nakken K.O., Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure. 2008;17:192-198. 2
  • [Weston et al., 2016] Weston J., Bromley R., Jackson C.F. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11:CD010224.
  • [Wide et al., 2000a] Wide K., Winbladh B., Tomson T., Kallen B. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia. 2000;41:854-861. 7
  • [Wide et al., 2000b] Wide K., Winbladh B., Tomson T., Sars-Zimmer K., Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev Med Child Neurol. 2000;42:87-92. 2
  • [Wide et al., 2002] Wide K., Henning E., Tomson T., Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr. 2002;91:409-414. 4
  • [Wilson et al., 2007] Wilson R.D., Genetics C., Motherisk. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29:1003-1013. 12
  • [Yerby et al., 1990] Yerby M.S., Friel P.N., Mccormick K. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res. 1990;5:223-228. 3
  • [Yerby et al., 1992] Yerby M.S., Friel P.N., Mccormick K. Antiepileptic drug disposition during pregnancy. Neurology. 1992;42:12-16. 4